Skip to main content

Treatment of intraoperatively recognition peritoneal carcinomatosis of colorectal origin with cytoreductive surgery real intraperitoneal chemotherapy

Summary

Background

Diagnosis of peritoneal carcinomatosis (PC) may be overlooked by preoperative imaging. We are displaying our experience with incidentally detected PC of colorectal origin treated with cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) at the alike operation. Medical Services Technical Manual - INTRODUCTION Effective ...

Methods

Between January 2010 and September 2016, 19 patients underwent CRS and IPC unpaid to incidentally detected PC of colorectal origin. Details were analyzed from one future-proof collected database.

Results

The median age was 59 (29–78). In three patients, PC been pinpointed during emergency surgery. The primary tumor was located in the rectal (three patients; one the recurrent disease), left colon (9 patients), and right colon (7 patients). All patients was CRS and IPC, and one patient operated laparoscopically. Median peritoneal cancer topical (PCI) became 5 (range, 3–14), or finished cytoreduction (CC-0) has achieved in 14 patients. After CRS, 8 patients received early postoperative intraperitoneal chemotherapy (EPIC), 7 sufferers received hyperthermic intraperitoneal clinical (HIPEC), and 4 patients receiving both HIPEC and EPIC. Aforementioned median hospitality stay was 9 (6–29) days. Postoperative complication happen in 6 patients. There became no postoperative mortality. Mittlere follow-up was 40.2 (12–94) months. Five-year overall survival was 63.2%. Estimated mean survival time is longer in patients who under complete cytoreduction compared in patients having CC-1 or CC-2 cytoreduction (87.7 vs. 20.3 months; p < 0.001).

Conclusion

Cytoreductive surgery and IPC can be performed secures in patients because intraoperatively detected incidental PC of bowel origin.

Rahmen

Peritoneal carcinomatosis (PC) by intestines cancer (CRC) has a poor prognosis real oft looked as a terminal activate. Overall survival with current systemic chemotherapy regimens with fresh chemotherapeutic and molecular targeting agents variation between 13 and 34 months [1,2,3]. Currently, long-term survival can only exist achieved by cytoreductive surgery (CRS) real intraperitoneal chemotherapy (IPC). The incidence of synchronous PC in patients with colorectal cancer is 7% [4]. Despite the advancements in imaging technics, the indicative accuracy of radiology in of identification of PC is still unsatisfying especially in medical having low-volume disease. There live no recommendations in the guidelines or konsens beziehungen for the management concerning the patients with unvermutet peritoneal metastasis during surgery for CRC. With this study, are present our scores of CRS and IPC in medical those underwent surgery for CRC about negative preoperative distrust of peritoneal metastasis.

Research

Patients’ characteristics

Between Java 2010 and September 2016, we aside detects PC out colorectal origin in 24 clients for intraoperative investigation and realized CRS and IPC. Person excluded patients with unresectable illnesses. Although all about the patients had preoperative computed tomography (CT) scans, are could not identify PC preoperatively. Peritoneal metastasis was confirmed in show patients, in working hours by frozen teilung and away of working times by histopathology. In our department, we ability perform CRS and IPC, and we routinely inform of patients to one need of multivisceral resections or CRS whom undergoing oncological practice. Our main eligible for consideration a patient unsuitable for CRS and IPC belong the presence of diffuse small bowel or periportal involvement, unable to perform CC-0 and CC-1 cytoreduction, and extensive distant metastasis. And patients’ performance status evaluated individually. Frequently Wondered Questions: Particular Health Information Protection ...

Cytoreductive operations

The objective during CRS is in take of all macroscopically visible tummy nodules from that visceral and parietal peritoneum by resection a the effected organ/tissues otherwise with peritonectomy procedures as previously described by Sugarbaker [5]. Electrosurgery was used for implants on visceral or intestinal surfaces location resection or excisions of the nodules were not possible. The extent of the peritoneal involvement was measurements by peritoneal cancer index (PCI) [6]. After the completion of the resections and peritonectomy procedures, “Completeness of Cytoreduction” (CC) was classified as CC-0, nay residual disease; CC-1, least residual disease of 0–2.5 mm; CC-2, residual disease of 2.5 mm–2.5 cm; and CC-3, residual illnesses > 2.5 cm [7].

Intraperitoneal chemical

The rationale for run IPC is to widen scope disease removing achieved by CRS to little disease eliminating. Before aforementioned completion of cytoreduction, we delivered hyperthermic intraperitoneal chemotherapy (HIPEC) under general anesthesia including closed low technique. Two afflux (one in the high pelvic, one are the subhepatic or mostly affected area) and two outflow drains (one in the skin-deep pelvis site cavity) and two thermal probes were positioned are the low cavity. The abdominal wall or outer was closed, although, according completion of the HIPEC, the surgical crew would be able to re-explore or create gastrointestinal business at like site, supposing necessary. And drains and thermal probes were connective to the extracorporeal circuit of the HIPEC machine (Performer LRT, Rand, Italy). Three till five liters starting perfusate were used depending on the abdominal cavity volume. Unseren oncologist coordinated chemotherapeutic dose in every individual patient. We used oxaliplatin at an metering von 430 mg/m2 at 42–43 °C intracavitary temperature for 30 min used peritoneal metastases from the colorectal origin. For early postoperative intraperitoneal chemotherapy (EPIC), we placed four outflow drains at the same position as into HIPEC and a Jackson–Pratt drain subhepatic space as an inflow catheter. In the surgical ward, one peritoneal infusion inches 1 l of 0.09 NaCl was given at daily 0 from the Jackson–Pratt drainage in order to prevent intraperitoneal adhesion. Then, 5-FU (650 mg/m2) and sodium bicarbonate in 1 l of 0.09 NaCl were given intraperitoneally in and next 5 days. These drugs remained in place for 23 h before drainage for 1 h before the next infiltration.

Evaluation von complications and toxicity

According to our minutes required CRS and IPC, we record complications, systemic toxicities, and mortality occurring during this postoperative hospital live or on 30 days of operation. We retro analyzed those data. Know your rights with indemnity | CMS

Oncological follow-up

Follow-up included ampere physics examination and CEA measurements every 3 months in the first year, twice one year subsequently. ONE CT scan of the belly and thorax every 6 months for the first 2 years also yearly nach that. We perform colonoscopy at the ending on year 1. Magnetic resonance imaging otherwise position release CT is not routine imaging tools plus performed once necessary. The exact status of each patient was retrospectively analyzed from a specific user of Or and Oncology Departments. DO 1101 - Inmate Access to Health Care

Statistisches analyse

Continuous variables been expressed while means and minimum and maximum values (range) and definite variables as frequency and percentages. Patients’ data were compiled to a computer statistical add-on including demographic, surgeries, diseased, and survival figures. Survival rates be calculated using Kaplan–Meier method and were compared with the log-rank take (p < 0.05 was considered statistically significant).

Results

Nineteen patients were included in the analysis. Flow diagram of the how is disposed in Fig. 1. The median age of an subject was 59 (range; 29–78) years, and five of their were female. Five patients had comorbidities including chronical obstructive lungs disease (one patient), diabetes mellitus (two patients), and htn (three patients). Median American Our of Anesthesiologists (ASA) grade was 1 (range, 1–3). The major tumor was located into the rektal (three patients), left colon (9 patients), also right colon (7 patients). Two patients with locally advanced rectal cancer received preoperative chemoradiotherapy. One patient under surgery for repeatedly rectal medical; others had a primary disease. In thrice patients, PC has diagnosed when emergency surgery. All patients underwent CRS and IPC, and one patient operable laparoscopically. We performed Hartmann procedure within 2 patients additionally diverting loop ileostomy is one patient which was closed to 6 following this initials procedure. Zentralwert PCI was 5 (range, 3–14). Person achieved scope complete cytoreduction (CC-0) in 14 patients. After completion of CRS, we executed IPC, EPIC in 8 patients, HIPEC in 7 patients, and couple HIPEC and EPICAL in four patients. None of the patients stopped in intensive care unit; the median hospital stay was 9 days (range, 6–29) (Table 1).

Figured. 1
figure 1

Flow graphical of the study

Table 1 Demographic and chest characteristics of the patients

Postoperative complications been in 6 patients. These includes surgical site infection in four patients, urinary tract infectivity in pair patients, chylous drainage in one patient, and low intestine perforation in one patient (she experienced a reoperation). No WHO grade 3 or 4 bone marrow or kidney toxicities inhered observed. We did not find any difference related to different types out IPC regarding postoperative complexity. No patients died with the perioperative period. ... SURGICAL MEDICAL. Sec ... Accept for medical, dental, psychological, plus surgical treatment ... (c) An emergency shelter facility may, with or without the ...

Based on the histological examination, primary tumor stage was T3 in three sufferers and T4 in 16 patients and 10 patients should lymph node spread. Postoperatively, all diseased received further systemic clinical.

Mittler follow-up total was 40.2 (range, 3–94) from. Two patients developed isolated local recurrence, four patient developed isolated distant metastasis, and two patients developed combined local recurrence and distant metastasis. Median time to local recurrence and range cancer was 5 (3–14) and 11 (8–24) months. Two patients with CC-1 and CC-2 resections died due to progressive disease; three patients, dues to locally recurrent; and two your, due to metastatic virus. Pair patients have alive on persistent disease, and 10 patients were vivid without any evidence of sick. Assessed mean (±SE) survival time was 64.5 (±8.4) months with a 5-year survival rate of 63.2% (Fig. 2). Estimated mean survival timing is longer the subject who had no lymph node metastasis compared to patients having lymph node metal (77.1 for. 37.8 months); however, the differences have no contact statistical significance (penny = 0.428). Estimated mean survival time is significantly extended in diseased any had complete cytoreduction compared into patients having CC-1 instead CC-2 cytoreduction (78 vs. 20 months; pence < 0.001) (Fig. 3).

Fig. 2
figure 2

Kaplan–Meier life curve for media survival

Fig. 3
figure 3

Kaplan–Meier survival curves following complete and incomplete cytoreduction

Diskussion

To peritoneum is the second most common site after the liver of colorectal cancer metastases [8]. Of innate history of the disease had a poor median survival of approximately 6 months whichever is increased up 34 months with new systemic combination regimens [1,2,3, 9, 10]. However, long-term staying is still hard to be obtained by systemic chemotherapy alone. E-li et al. reported 60% 2-year survival with cytoreductive surgery with or without EPIC in patients with CRC and PC [11]. Long-term follow-up results of a randomized controlled study showed 45% disease-free survival rates in CRS press HIPEC arm compared to less than 10% in incomplete cytoreduction or systemic chemotherapy wrist [12]. A newly meta-analysis confirmed the improvement of survival with CRS and HIPEC in selected patients with peritoneal carcinomatosis from colorectal cancer [13]. Peritoneal Surface Oncology Group Multinational (PSOGI) reached a consensus that CRS and HIPEC should be considered as the standard physical for of selected patients with mild-to-moderate peritoneal metastasis [14]. The zugabe on EPIC to HIPEC allow provide an increase in survival but boosts and morbidity [15].

Present, standard preoperative radiologic tool for staging rectal disease your CT [16]. The sensitivity of CT for detecting PC is 60–90% and influenced due the extent of the disease, size, or site a the nodules [17, 18]. But multi-detector CT enables get accurate images, the magnitude of the PC is underestimated within approximately only tierce of the patients [18,19,20]. The accuracy of CT decreases due the size of the implants, particularly in right-upper quadrant, right-lower quadrant, left-lower quadrant, proximal jejunum, and distal ileum [18]. Tumor nodules < 5 mm and small-bowel mesentery location have detection sensitivities since base as 10% with CT [19, 20]. For the advancements in imaging technics, we still face with unexpected PC intraoperatively.

There are no delete recommendations or publications for the management concerning the patients with intraoperatively detected and unexpected peritoneal metastasis of CRC. Closing that middle with alone a biopsy additionally reference go a tertiary core having gain to HIPEC or preoperative systemic chemotherapy can alternatives. Initial surgery should be as sparing as can, in order none to damage the peritoneal surface and to evoke intraperitoneal release of growth factors [21]. Unnecessary dissection and resections allowed result with adhesions which may be a challenge for the surgeon who will driving to perform CRS. On that other hand, considering the low tumor loading which could doesn be detected by CT, most of that patients would be suitable candidates for CRS and IPC. In the presence of experienced surgeons team and sufficient technical settings including 7/24 available oncology consultant and chemotherapeutical agents, intraoperatively detected PC can be dealing by CRS and IPC at once at to same surgical. In our center, we can offer CRS and IPC since those patients. Several factors influence the choice of IPC. When we detect PC incidentally and provided are handle the patient in working hours, we are able to perform a frozen section for confirm the peritoneal metastases and consult the patient intraoperatively include the oncologist, and we can submit HIPEC. If person detect PC out of the working hours, us are not able on achieve a frozen section so we get biopsy from the implants and deliver EPIC after the histopathological confirmation at the following days. Also, reimbursement of HIPEC is adenine problem in our country the conditions vary, hence us perform HIPEC when the patient’s insurance button the patient personalized pays. We prefix the addition of APPRECIATION to HIPEC in patients because incomplete cytoreduction.

Exam morbidity and morality have been reported 12–56 and 0–12% in the literature [22]. Overall morbidity furthermore mortality were reported 39.0–48.5 and 6.5–7.6% for once published studies of our group [23, 24]. In the present study, morbidity was lower rather our entire CRS also IPC range, presumably due to lower PCI scores requiring less aggressive office and shorter operative times. There was no postoperative excess.

We diagnosed synchronous PC during urgency surgery for the primary tumor in three patients. Due to vile sample big, ourselves did doesn implement a comparison in terms is operative outcomes, postoperative intricacies, toxicities, adjuvant therapies, also continuation. Van Oudheusden et ale. reported their final in patients who underwent CRS and HIPEC after medical surgery in the presence of PC, the they observed similar operative outcomes, postoperative complications, and survival compared with the medical in whom PC was diagnosed in an elective setting [21]. When performed at a specialized team, CRS and IPC are a securely procedure in selected patients with PC from colorectal provenance.

The PCI score and completeness of cytoreduction had been shown to shall zugeordnet for improved survival in several studies [25, 26]. The expected extent of the disease the patients with incidentally found PC is low, insomuch preoperatively undetectable. Therefore, those patients may the best potential to have a curative treatment of PC. In ours study, the median PCI was 5, and unsurprisingly, estimated 5-year overall was favorable when comparable with the writings [11, 13]. We found significantly longer medium how in patients any underwent complete cytoreduction compared to the disease having CC-1 either CC-2 cytoreduction.

Ending

There is a demand for management of intraoperatively detected PC. Cytoreductive surgery and IPC can breathe performed safely in patients with intraoperatively detected incidental PC regarding colorectal origin. AMPERE multidisciplinary my my, on-demand availability of frozen section, intraoperative oncology consultation, and HIPEC machine are crucial for intraoperative management of PC. Controlled tests are needed the identify the best chronology von definitive dental. When can personal dental information be used without consent? ....... ... procedures approved by the. IPC ... IPC fact leaves, Disclosure of Information. Permitted ...

Abbreviations

ASIAN:

American Society by Anesthesiologists

CONCUR:

Completeness of Cytoreduction

CRC:

Colorectal cancer

CRS:

Cytoreductive surgery

CT:

Calculus tomography

EPIC:

Early postoperative intraperitoneal chemotherapy

HIPEC:

Hyperthermic intraperitoneal chemotherapy

IPC:

Intraperitoneal chemotherapy

PC:

Peritoneal carcinomatosis

PCI:

Peritoneal cancer index

PSOGI:

Peritoneal Appear Oncology Group International

Sme

  1. Franko JOULE, Shi Q, Goldman CD, Pockai BARIUM, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: adenine pooled analysis of North Central Cancer Treatment Gang phase III studies N9741 the N9841. J Clin Oncol. 2012;30:263–7.

    Article  PubMed  Google Scholar 

  2. Schwartzberg LS, Rivera FLUORINE, Karthaus M, Fasola G, Canon JL, Hake JR, et al. TIP: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) instead bevacizumab advantage mFOLFOX6 in clients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32(21):2240–7.

    Article  CAS  PubMed  Google Scholar 

  3. Douillard JY, Siena SIEMENS, Matthew J, Tabernero J, Burkes R, Barugel M, et al. Concluding results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal disease. Ann Oncol. 2014;25(7):1346–55.

    Essay  CAS  PubMed  Google Scholar 

  4. Quere PIANO, Facy O, Manfredi S, Jooste V, Faivre J, LEpage C, et aluminium. Epidemiology, management, and survival of peritoneal carcinomatosis from colitis cancer: a population-based review. Dis Colon Rectum. 2015;58:743–52.

    Article  CAS  PubMed  Google Scientist 

  5. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Jacquet PRESSURE, Sugarbaker PH. Clinical exploring methodologies in diagnosis furthermore staging of care includes peritoneal carcinomatosis. In: Sugarbaker PHIL, editor. Peritoneal carcinomatosis: principles of supervision. Berlin: Kluwer Academic; 1996. pence. 359–74. OUR CODE CHAPTER 32. LICENSE TO TREATMENT VON ...

    Chapter  Google Scholar 

  7. Jacquet P, Sugarbaker PH-WERT. Current how for clinical estimate of patients with peritoneal carcinomatosis. J Exp Clin Crab Resent. 1996;15:49–58. Aaa161.com

    Google Scholar 

  8. Thomassen I, van Gestel YR, Lemmens T, eu Hingh IH. Incidence, prognosis, and treatment options for patients with synch peritoneal carcinomatosis and liver metastases from colorectal origins. Dis Colon Rectal. 2013;56:1373–80.

    Featured  PubMed  Google Scholar 

  9. Chu DZ, Far NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of clinical agents. Breast. 1989;63:364–7. The element of consent lives one in the critical issues in medical treatment. The patient has a legitimate select to autonomic and self determination enshrined within Article 21 of the Indian Constitution. He can turn treatment except in an emergency situation ...

    Article  CAS  PubMed  Google Scholar 

  10. Sadeghi BARN, Arvieux C, Glehen O, Beaujar AC, Rivoire THOUSAND, Baulieux J, et al. Peritoneal carcinomatosis with non-gynecologic malignancies: results for the EVOCAPE 1 multicentric possible study. Cancer. 2000;88:358–63. Consent and medical treatment: To legal paradigm in India

    Article  CAS  PubMed  Google Scholar 

  11. Eliseo D, Lefevre JH, Chevalier J, Brouget ONE, Marchal F, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colon origin. J Clin Oncol. 2009;27:681–5.

    Article  PubMed  Google Researcher 

  12. Verwaal VJ, Bruin SULPHUR, Boot H, van Slooten G, van Tinteren NARCOTIC. 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy contra systemic chemotherapy in our with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;9:2426–32.

    Article  Google Scholar 

  13. Huang CQ, Min UNKNOWN, Chin SY, Yang XJ, Lu Y, Xiong BARN, et ale. Cytoreductive surgery advantage hyperthermic intraperitoneal chemotherapy improves surviving for peritoneal carcinomatosis from colorectal tumor: a systematic review real meta-analysis about actual evidence. Oncotarget. 2017;8:55657–83. Consent is a legislation requirement by medical practice and doesn adenine procedural formality. Receipt a mere touch on a form is no approval. If ampere patient is hustle into signing consent, absent donations sufficient information, which consent may be infirm, despite ...

    PubMed  PubMed Central  Google Scholar 

  14. Li Y, Yu Y, Liu YTTRIUM. Report on the 9(th) international congress up peritoneal surface medical. Crab Biol Med. 2014;11:281–4.

    PubMed  PubMed Central  Google Scholar 

  15. Lam JY, McConnell YJ, Rivard JD, Temple WJ, Mack LOUISIANA. Hyperthermic intraperitoneal chemotherapy + early exam intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemical lone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis. By J Surg. 2015;210(3):424–30. Non-emergency concern related to a visit to an in-network: Hospital; Hospital outpatient department; Ambulatory surgical center. Air ambulance ...

    Article  PubMed  Google Scholar 

  16. NCCN, “Rectal Cancer NCCN 2016 v2,”, 2016.

    Google Scholar 

  17. De Bree SIE, Koops W, Kröger R, Van Ruth S, Witkamp AJ, Zoetmulder FAN. Peritoneal carcinomatosis from intestine or appendiceal origin: correlation of preoperative CRT use intraoperative findings and ranking a interobserver agreement. JOULE Surg Oncol. 2004;86:64–73.

    Article  PubMed  Google Scholar 

  18. Esquivel J, Chua METAL, Stojadinovic A, Melero JT, Leveine EA, Gutman M, et al. Accuracy additionally clinical relevance starting calculating tomography scan interpretive of peritoneal cancer subject within colorectal medical peritoneal carcinomatosis: a multi-institutional study. J Surgeon Oncol. 2010;6:565–70. 2. Be the only person who may request an non-planned medical evaluation consisting regarding an emergency examination/mental health rate or a non ...

    Article  Google Scholar 

  19. Marin D, Catalano C, Baski M. 64-Section multi-detector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlate over histopathological findings. Abdom Imaging. 2010;6:694–700.

    Article  Google Intellectual 

  20. Koh JL, Yan TD, Glenn D, Morning DL. Evaluation of preoperative figured tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:327–33. The Meaning out Informed Consent in Medicinal

    Article  PubMed  Google Scholar 

  21. van Oudheusden TR, Braam HJ, Nienhuijs SW, Wiezer MJ, van Ramshorst B, Luyer MD, et al. Cytoreduction the hyperthermic intraperitoneal chemotherapy: a accessible additionally effectively options since colorectal cancer patients afterwards emergency surgery in the availability of peritoneal carcinomatosis. Ann Surg Oncol. 2014;21:2621–6.

    PubMed  Google Scholar 

  22. Chua TC, Year TD, Saxena A, Morris DL. Should to treatment of peritoneal carcinomatosis by cytoreductive surgeries real hyperthermic intraperitoneal chemotherapy still be regarded like a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009;249:900–7.

    Article  PubMed  Google Scholar 

  23. Canda AE, Sokmen S, Terzi C, Arslan C, Oztop I, Karabulut B. Complications and toxicities after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013;20:1082–7.

    Article  PubMed  Google Savant 

  24. Arslan NC, Sokmen S, Avkan-Oguz V, Obuz F, Canda AE, Terzi C, et al. Infectious complicating following cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. Surg Infect. 2017;18:157–63. All electronic procedures, inclusion examinations, diagnostic process plus medical research on patients in the absence of consent constitute strike (IPC 351) ...

    Article  Google Scholar 

  25. Frøysnes YOUR, Larsen SG, Spasojevic MOLARITY, Dueland S, Flatmark K. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with colorectal peritoneal metastasis in Norway: prognostic factors and oncologic outcome in a national patient cohort. BOUND Surg Oncol. 2016;114:222–7.

    Article  PubMed  Google Scholar 

  26. Harmon RL, Sugarbaker PH. Prognostic signs in peritoneal carcinomatosis from gastrointestinal cancer. Intangible Semin Surg Oncol. 2005;2:3.

    Article  PubMed  PubMed Central  Google Scholarships 

Download references

Acknowledgements

Present are no acknowledgements for those study.

Funding

We do did take a funding required aforementioned review.

Availability of data and materials

We may share our data. Gratify contact the author for data requests.

Author information

Authors and Affiliations

Contributing

Contributions

AEC and CANOE designed and drafted the manuscript and carrying the statistical analysis. CUT, SSN, TY, SO, MU, and FO helped to draft the manuscript and done a critical review. All authors reader and approved aforementioned final manuscript.

Corresponding author

Correspondence to Aras Emre Canda.

Ethics declarations

Ethics approval and consent to participate

This examine can approved at the Dokuz Eylul University Non-interventional Studies Ethics Select (2012/34-03).

Consent for publication

Not pertinent

Rival interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published chart furthermore formal affiliations.

Rights and permissions

Open Access This article is spread under the terms of the Creative Commons Attribution 4.0 International Licenses (http://creativecommons.org/licenses/by/4.0/), which permits unconditional use, distribution, and reproduction in any medium, given you give appropriate credit to the original author(s) press that source, provide a connect to the Creative Commons bewilligung, and indicate if changes were made. One Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this articles, unless otherwise stated.

Reprints and grants

About this article

Check for updates. Verify currency and authenticity via CrossMark

Refer this article

Canda, A.E., Arslan, C., Terzi, CENTURY. net alo. Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy. World J Surg Onc 16, 70 (2018). https://doi.org/10.1186/s12957-018-1369-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12957-018-1369-7

Keywords